Indian Pharma's Shift from Generics to Innovation: Why the Market is Underpricing the Sector

The Indian pharmaceutical industry is undergoing a massive structural transformation, moving away from being a mere "generics factory" toward becoming a global innovation powerhouse. According to Nandan Kulkarni, Director at Bernstein, this pivot is set to drive growth through 2035, yet the financial markets have yet to fully price in this fundamental change.

Moving Up the "Innovation Pyramid"

For decades, the valuation of Indian pharma companies was tied almost exclusively to their ability to manufacture and export off-patent generic drugs to the US market. However, Kulkarni argues that this playbook is becoming obsolete. Indian biopharma firms are now aggressively shifting capital allocation toward higher-margin, complex segments.

The industry is witnessing a surge in hiring across specialized fields, including biotechnology, digital health, artificial intelligence, and advanced engineering. This talent influx is supporting a transition toward New Drug Applications (NDAs), 505(b)(2) filings, orphan drug designations, and specialty therapies. By climbing this "innovation pyramid," companies are moving into niches that offer significantly higher margins than traditional generics, creating a much more robust earnings profile.

The GLP-1 Revolution and Market Dynamics

One of the most significant growth levers identified is the rise of GLP-1 drugs, which are transforming the treatment of obesity and diabetes. Kulkarni predicts a major shift in the metabolic healthcare landscape, estimating that insulin's market share could drop to approximately 50% by FY31 as GLP-1 medications offer superior glycemic control and weight management.

For Indian players, this is a strategic win. Historically, insulin has been a lower-margin product. The shift toward GLP-1s and peptides allows Indian biopharma companies to move up the value chain, both by manufacturing off-patent versions and developing next-generation formulations. While the adoption in India may be slower than in North America due to socioeconomic factors, it promises a massive "second wave" of grassroots penetration.

The "China Plus One" Strategy Moves to Execution

While the "China plus one" supply chain diversification narrative has been discussed for years, Kulkarni believes the current environment is fundamentally different. Recent geopolitical tensions and the instability surrounding players like WuXi have shifted the industry from policy discussions to active execution.

Global innovators are now structurally realigning their supply chains to reduce dependency on China. Given India's deep expertise in biopharma and complex manufacturing, the country is positioned as a natural and necessary beneficiary of this global realignment.

A Disconnect Between Boardrooms and the Street

The core issue identified is a massive blind spot in consensus market thinking. While boardroom discussions in Indian pharma have shifted from "patent cliffs" to "innovation pipelines" and "global partnerships," the stock market still models these companies as simple chemistry and contract manufacturing entities. The market is failing to account for the depth of the innovation pivot and the high quality of the talent being integrated into the sector.

Key Takeaways